Biotechnology M&A » By The Online Investor Staff, updated Sun., Apr. 18, 5:41 AM
Recent mergers and acquisitions in the Biotechnology M&A category.
Slide #82. Spectrum Pharmaceuticals — Allos Therapeutics
| Acquirer: |
Spectrum Pharmaceuticals (SPPI) |
| Acquiree: |
Allos Therapeutics (ALTH) |
| Details: |
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology today announced the successful completion of the acquisition of Allos Therapeutics, Inc., on September 5, 2012 through a "short-form" merger of Sapphire Acquisition Sub, Inc., a wholly-owned subsidiary of Spectrum, with and into Allos with Allos surviving the merger and continuing as a wholly-owned subsidiary of Spectrum. |
Spectrum Pharmaceuticals is a biopharma company. Co.'s product portfolio consists of in-development drug products for the treatment of cancer patients. Co. has three drugs in development: ROLONTIS, which is a long-acting granulocyte colony-stimulating for chemotherapy-induced neutropenia; Poziotinib, which is an irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in development for treating relapsed or refractory non-Hodgkin's lymphoma patients (including diffuse large B-cell lymphoma).
SPPI SEC Filing Email Alerts Service
Open the SPPI Page at The Online Investor »
Spectrum Pharmaceuticals is a biopharma company. Co.'s product portfolio consists of in-development drug products for the treatment of cancer patients. Co. has three drugs in development: ROLONTIS, which is a long-acting granulocyte colony-stimulating for chemotherapy-induced neutropenia; Poziotinib, which is an irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in development for treating relapsed or refractory non-Hodgkin's lymphoma patients (including diffuse large B-cell lymphoma).
SPPI SEC Filing Email Alerts Service
Open the ALTH Page at The Online Investor »
| Company Name: |
| Spectrum Pharmaceuticals Inc |
| Stock buyback: |
| SPPI buyback |
| Website: |
| www.sppirx.com |
| Sector: |
| Biotechnology |
| Number of ETFs Holding SPPI: |
| 40 |
| Total Market Value Held by ETFs: |
| $121.11M |
| Total Market Capitalization: |
| $459.00M |
| % of Market Cap. Held by ETFs: |
| 26.38% |
|
Quotes delayed 20 minutes
|
